The correlation between FGF-21 and metabolic effect in patients with bipolar disorder

• In: Poster presentation
• At: Buenos Aires (Argentina) (2016)
• Type: Poster
• Poster code: POS-TRI-003
• By: CHANG, Hui Hua (National Cheng Kung University, Institute of Clinical Pharmacy and Pharmaceutical Sciences, Tainan, China Taiwan)
• Co-author(s): Hui Hua Chang:Institute of Clinical Pharmacy and Pharmaceutical Sciences,National Cheng Kung University,Tainan,Taiwan, Province of China|Yung Wen Cheng:Institute of Clinical Pharmacy and Pharmaceutical Sciences,National Cheng Kung University,Tainan,Taiwan, Province of China|Po Wu Gean:Department of Pharmacology,National Cheng Kung University,Tainan,Taiwan, Province of China|Po See Chen:Department of Psychiatry,National Cheng Kung University,Tainan,Taiwan, Province of China
  
• Abstract:

  Fibroblast growth factor-21 (FGF-21) is a novel endogenous regulator of glucose and lipid metabolism. Recent report indicated that FGF-21 is also a mediator of the neuroprotective effects of mood stabilizers in animal study. In addition, patients with bipolar disorder (BD) had high risk of metabolic abnormalities, but the role of FGF-21 in BD..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login